A large pharmaceutical company in partnership with a leading biologics company were preparing for the launch of a blockbuster monoclonal antibody in immunology.  They had full development programs for two indications in place, but felt the compound could address a variety of additional indications.  We conducted a Multi-Variable Analysis to recommend disease areas that provided opportunity and fit with this biologic.

A mid-sized biotechnology company had a portfolio of products all focused on orphan diseases.  They wanted to provide access to all patients around the globe, and asked us to evaluate the market access processes not only in leading industrialized markets, but across all countries where there might be significant patient need.